- Home
- KPRX vs ASPS Comparison
KPRX vs ASPS Comparison
Compare KPRX & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- ASPS
- Stock Information
- Founded
- KPRX 1998
- ASPS 1999
- Country
- KPRX United States
- ASPS Luxembourg
- Employees
- KPRX N/A
- ASPS N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ASPS Other Consumer Services
- Sector
- KPRX Health Care
- ASPS Consumer Discretionary
- Exchange
- KPRX Nasdaq
- ASPS Nasdaq
- Market Cap
- KPRX 9.1M
- ASPS 9.2M
- IPO Year
- KPRX N/A
- ASPS N/A
- Fundamental
- Price
- KPRX $3.08
- ASPS $6.29
- Analyst Decision
- KPRX Strong Buy
- ASPS
- Analyst Count
- KPRX 1
- ASPS 0
- Target Price
- KPRX $10.00
- ASPS N/A
- AVG Volume (30 Days)
- KPRX 1.3M
- ASPS 18.4K
- Earning Date
- KPRX 05-09-2025
- ASPS 07-24-2025
- Dividend Yield
- KPRX N/A
- ASPS N/A
- EPS Growth
- KPRX N/A
- ASPS N/A
- EPS
- KPRX N/A
- ASPS N/A
- Revenue
- KPRX $20,000.00
- ASPS $164,104,000.00
- Revenue This Year
- KPRX N/A
- ASPS $38.29
- Revenue Next Year
- KPRX N/A
- ASPS N/A
- P/E Ratio
- KPRX N/A
- ASPS N/A
- Revenue Growth
- KPRX N/A
- ASPS 13.12
- 52 Week Low
- KPRX $2.51
- ASPS $3.46
- 52 Week High
- KPRX $5.55
- ASPS $16.24
- Technical
- Relative Strength Index (RSI)
- KPRX 48.79
- ASPS 46.48
- Support Level
- KPRX $2.90
- ASPS $5.90
- Resistance Level
- KPRX $4.18
- ASPS $6.51
- Average True Range (ATR)
- KPRX 0.26
- ASPS 0.53
- MACD
- KPRX 0.00
- ASPS -0.02
- Stochastic Oscillator
- KPRX 19.12
- ASPS 52.30
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.